Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARD und Biologicals bei entzündlich-rheumatischen Erkrankungen

Pieringer H, Stuby U, Biesenbach G (2007) Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum 36:278–286

Widmer AF (2001) New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 33(Suppl 2):S94–S106

Ruyssen-Witrand A, Gossec L, Salliot C et al (2007) Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25:430–436

Den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695

Bongartz T, Halligan CS, Osmon DR et al (2008) Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 59:1713–1720

Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293

Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61

Jain A, Witbreuk M, Ball C, Nanchahal J (2002) Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am 27:449–455

Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131

Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54:628–634

Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920

Dixon WG, Kezouh A, Bernatsky S, Suissa S (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 70:956–960

Härle P, Straub RH, Fleck M (2010) Perioperative management of immunosuppression in rheumatic diseases–what to do? Rheumatol Int 30:999–1004

Scanzello CR, Figgie MP, Nestor BJ, Goodman SM (2006) Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J 2:141–147

Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients (corrected). Foot Ankle Int 24:40–44

Dvivedi S, Tiwari SM, Sharma A (1997) Effect of ibuprofen and diclofenac sodium on experimental would healing. Indian J Exp Biol 35:1243–1245

Visser K, Katchamart W, Loza E et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093

Bombardier C, Hazlewood GS, Akhavan P et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 39:1583–1602

Luqmani R, Hennell S, Estrach C et al (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48:436–439

Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44:157–163

Koike R, Takeuchi T, Eguchi K et al (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451–458

Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784

OCEBM Levels of Evidence Working Group*. „The Oxford 2011 Levels of Evidence“. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653

Loza E, Martinez-Lopez JA, Carmona L (2009) A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 27:856–862

Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214–217

Sany J, Anaya JM, Canovas F et al (1993) Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20:1129–1132

Sreekumar R, Gray J, Kay P, Grennan DM (2011) Methotrexate and postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery–a ten year follow-up. Acta Orthop Belg 77:823–826

Murata K, Yasuda T, Ito H et al (2006) Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 16:14–19

Perhala RS, Wilke WS, Clough JD, Segal AM (1991) Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 34:146–152

Tanaka N, Sakahashi H, Sato E et al (2003) Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 9:115–118

Fuerst M, Möhl H, Baumgärtel K, Rüther W (2006) Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 26:1138–1142

Rehart S, Petak N (2007) Moderne rheumatische Basistherapie perioperativ. Akt Rheumatol 32:74–77

Van Riel PLCM, Smolen JS, Emery P et al (2004) Leflunomide: a manageable safety profile. J Rheumatol 31(Suppl 71):21–24

Barnard AR, Regan M, Burke FD et al (2012) Wound healing with medications for rheumatoid arthritis in hand surgery. ISRN Rheumatol 2012:251962

Escalante A, Beardmore TD (1995) Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 22:1844–1851

Cunha BM da, Maria Henrique da Mota L, Dos Santos-Neto LL (2012) Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy. Int J Rheumatol 2012:369565

Goh L, Jewell T, Laversuch C, Samanta A (2012) Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 32:5–13

Pieringer H, Danninger K, Tzaribachev N et al (2013) Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review. Yonsei Med J 54:253–257

Giles JT, Bartlett SJ, Gelber AC et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55:333–337

Kawakami K, Ikari K, Kawamura K et al (2010) Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49:341–347

Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331–335

Kubota A, Nakamura T, Miyazaki Y et al (2012) Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 22:844–848

Talwalkar SC, Grennan DM, Gray J et al (2005) Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64:650–651

Wendling D, Balblanc JC, Brousse A et al (2005) Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 64:1378–1379

Gilson M, Gossec L, Mariette X et al (2010) Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 12:R145

Pham T, Bachelez H, Berthelot JM et al (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78(Suppl 1):15–185

Nishida K, Nasu Y, Hashizume K et al (2013) Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol (Epub ahead of print)

Pham T, Bachelez H, Berthelot JM et al (2012) Abatacept therapy and safety management. Joint Bone Spine 79(Suppl 1):3–84

Kaufmann D, Arbogast M (2010) Prä- und postoperatives Management von Patienten unter Rituximabtherapie. Akt Rheumatol 35:368–388

Momohara S, Hashimoto J, Tsuboi H et al (2012) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol (Epub ahead of print)

Hirao M, Hashimoto J, Tsuboi H et al (2009) Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68:654–657

Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357